Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER_GOV 1OTHER 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 9Prostatic Hyperplasia 3Neoplasms 1

Interventions

Dutasteride 3proxalutamide 1TroVax 1Therapeutics 1Standard of Care 1Prostatectomy 1Docetaxel 1Adrenergic alpha-Antagonists 15-alpha Reductase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Hyperplasia × Dutasteride × Clear all
NCT00883909 2017-07-11

ARI103094-Follow-Up Study for REDUCE Study Subjects

GlaxoSmithKline

Completed
2,795 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT01337258 2017-05-30

Economic Analyses of the REDUCE Trial

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Neoplasms, Prostatic Hyperplasia, Prostatic Neoplasms

NCT00375765 2017-01-19

Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer

GlaxoSmithKline

Phase 4 Completed
40 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡